Effects of tamoxifen on the cervix and uterus in women with breast cancer: Experience with Iranian patients and a literature review

Asian Pacific Journal of Cancer Prevention

Volumn 10, Issue 4, 2009, Pages 595-598

  Zarchi, Mojgan Karimi ^a   Behtash, Nadereh ^b   Sekhavat, Leila ^a   Dehghan, Atefeh ^a  

^a SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cervical cancer; Pap smear; Tamoxifen breast cancer; Uterine cancer

Indexed keywords

EID: 77951126554     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Abadi MA, Barakat RR, Saigo PE (2000). Effects of tamoxifen on cervicovaginal smears from patients with breast cancer. Acta Cytol, 44, 141-6.
2. Athanassiadou PP, Kyrkou KA, Antoniades LG, et al (1992). Cytological evaluation of the effect of tamoxifen in premenopausal and post-menopausal women with primary breast cancer by analysis of the karyopyknotic indices of vaginal smears. Cytopathology, 3, 203-8.
3. Behtash N, Hashemi R, Karimi Zarchi M(2009). Uterine malignancy following tamoxifen use in breast cancer patients in Iran: case series and literature review. Asian Pac J Cancer Prev, 10, 163-6.
4. Behtash N, Karimi Zarchi M (2007). Cervical cancer and the role of HPV. Tumor J, 61, 1-5.
5. Behtash N, Mehrdad N (2006). Cervical cancer: screening and prevention. Asian Pac J Cancer Prev, 7, 683-6.
6. Behtash N, Hashemi R, Karimi Zarchi M (2009). Uterine malignancy following tamoxifen use in breast cancer patients in Iran: case series and literature review. Asian Pac J Cancer Prev, 10, 163-6.
7. Berry DA, Cronin KA, Plevritis SK, et al (2005). Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med, 353,1784.
8. Bissett D, Davis JA, George WD (1994). Gynaecological monitoring during tamoxifen therapy. Lancet, 344, 1244.
9. Boccardo F, Bruzzi T', Rubagotti A, et al (1981). Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology, 38, 281-5.
10. Cohen I, Rosen DJD, Altaras M, et al (1994). Tamoxifcn treatment in premopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations, and fibroid overgrowth. Br J Cancer, 69, 620-1.
11. Curtis RE, Boice JD, Shriner DA, et al (1996). Second cancers after adjuvant therapy for breast cancer. J Natl Cancer Inst, 8, 332-4.
12. Deligdisch L, Kalir T, Cohen CJ, et al (2000). Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol, 78, 181-6.
13. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365, 1687.
14. Eells TP, Alpern HD, Cirzywacz C, et al (1990). The effect of tamoxifen on cervical squamous maturation in Papanicolaou stained cervical smears of post-menopausal women.. Cytopathology, 1, 263-8.
15. Emens LA, Davidson NE (2003). The follow-up of breast cancer. Semin Oncol, 30, 338.
16. Ferrazzi E, Cartci G, Mattarazzo R, et al (1977). Estrogen-like effect of tamoxifen on vaginal epithelium. BMJ, 60, 1351-2.
17. Fisher B, Costantino JP, Redmond CK, et al (1994). Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst, 86, 527-37.
18. Fornander T, Rutqvist LE, Cedermark B, et al (1989). Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet, 1, 117-20.
19. Fornander T, Rutqvist LE, Wilking N (1991). Effects of tamoxifen on the female genital tract. Ann NY Acad Sci, 622, 469-76.
20. Ghaemmaghami F, Karimi Zarchi M, Mousavi A, et al (2008). Results of cervical cone excision biopsy in Iran. Asian Pac J Cancer Prev, 9, 45-7.
21. Gill BL, Simpson JF, Somlo G, et al (1998). Effects of tamoxifen on the cytology of the uterine cervix in breast cancer patients. Diagn Cytopathol, 19, 417-22.
22. Jemal A, Siegel R, Ward E, et al (2007). Cancer statistics. CA Cancer J Clin, 57, 43.
23. Khatcheressia JL, Wolff AC, Smith TJ, et al (2006). American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-up and Management Guidelines in the Adjuvant Setting. J Clin Oncol, 24, 5091-7.
24. Killackey MA, Hakes TB, Pierce VK (1985). Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep, 69, 237-8.
25. Leslie KK, Walter SA, Torkko K, et al(2007). Effect of tamoxifen on endometrial histology, hormone receptors, and cervical cytology: a prospective study with follow-up. Appl Immunohistochem Mol Morphol, 15, 284-93.
26. Livolsi VA, Salhany KE, Dowdy YG (1995). Endocervical adenocarcinoma in Tamoxifen-treated patients. Am J Obstet Gynecol, 172, 1065.
27. Magriples U, Naftolin F, Schwartz PE, et al(1993). High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol, 11, 485-90.
28. Mignotte H, Lasset C, Bonadona V, et al (1998). Iatrogenic risk of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC). Int J Cancer, 76, 325-30.
29. Mortimer JE, Boucher L, Baty J, et al (1999). Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol, 17, 1488-92.
30. Mousavi A, Karimi Zarchi M, Gilani MM, et al (2008). Radical hysterectomy in the elderly. World J Surg Oncol, 6, 38.
31. Mousavi A, Karimi Zarchi M (2007). Isolated cervical metastasis of breast cancer: a case report and literature review. J Low Genit Tract Dis, 11, 276-8.
32. Mousavi M (2007). Iranian Cancer Care Center (book), chapter 1; Womens cancer in Iran,7-10
33. Rayter Z, Gazet JC, Shepherd J, et al (1994). Gynaecological cytology and pelvic ultrasonography in patients with breast cancer taking tamoxifen compared with controls. Eur J Surg Oncol, 20, 134-40.
34. Rutqvist LE, Johansson H, Signomklao T, et al (1995). Adjuvant Tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast cancer study group. J Natl Cancer Inst, 87, 645.
35. Senkus-Konefka E, Konefka T, Jassem J (2004). The effects of tamoxifen on the female genital tract. Cancer Treat Rev, 30, 291-301.
36. Sismondi P, Biglia N, Volpi E, et al (1994). Tamoxifen and endometrial cancer. Ann NY Acad Sci, 734, 310-21.
37. Sonnendecker HE, Cooper K, Kalian KN (1994). Primary fallopian tube adenocarcinoma in situ associated with adjuvant tamoxifen therapy for breast carcinoma. Gynccol Oncol, 52, 402-7.
38. Wickerhan L (2002). Tamoxifen-An update on current data and where it can naw be used. Breast Cancer Res Treat, 7, S7.
39. Wickerham DL, Fisher B, Wolmark N, et al (2002). Association of tamoxifen and uterine sarcoma. J Clin Oncol, 20, 2758-60.
40. Wolf DM, Jordan VC (1992). Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Gynccol Oncol, 45, 118-28.
41. Yang YJ, Trapkin LK, Demoski RK, et al (2001). The small blue cell dilemma associated with tamoxifen therapy. Arch Pathol Lab Med, 125, 1047-50.